ArticleMedical cannabis and cannabinoids2019
Development of a Novel Nano-emulsion Formulation to Improve Intestinal Absorption of Cannabidiol.
Article in Medical cannabis and cannabinoids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 102 citations in OpenAlex.
- A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.Cannabis and cannabinoid research · 2022Trial
- ACPA decreases non-small cell lung cancer line growth through Akt/PI3K and JNK pathways in vitro.Cell death & disease · 2021Trial
- Subchronic Exposure to Low-Dose Cannabidiol (CBD) and ΔPathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Cannabidiol in Dietary Supplements: Characteristics, Routes of Administration, Bioavailability, and Research Challenges.Molecules (Basel, Switzerland) · 2026Review
- Cannabidiol for Mucosal Diseases: Therapeutic Potential and Advanced Delivery Strategies.Pharmaceutics · 2026Review
- An Accurate Method Based on Ultra-High-Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry for the Quantification of Five Cannabinoids in Juvenile and Adult Caenorhabditis elegans.Journal of separation science · 2026Article
- New Strategies to Improve Drug Solubility and Its Impact on Bioavailability: A Patent Review (2015-2024).AAPS PharmSciTech · 2025Review
- Innovative Strategies to Enhance the Bioavailability of Cannabidiol: Nanotechnology and Advanced Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Review
- Formulation and Functional Characterization of a Cannabidiol-Loaded Nanoemulsion in Canine Mammary Carcinoma Cells.Pharmaceutics · 2025Article
- Exploring the interconnected properties of cannabidiol suspensions and orodispersible films.Scientific reports · 2025Article
- Nanoemulsions of Cannabidiol, Δ9-Tetrahydrocannabinol, and Their Combination Similarly Exerted Anticonvulsant and Antioxidant Effects in Mice Treated with Pentylenetetrazole.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Understanding the Potential of CBD for Health Benefits: An Overview.Current drug discovery technologies · 2025Review
- Public health considerations about tetrahydrocannabinol-infused beverages.Addiction (Abingdon, England) · 2025Article
- Development and characterization of a zeolite based drug delivery system: Application to cannabidiol oral delivery.Heliyon · 2024Article
- Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies.Drug delivery and translational research · 2024Article
- Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.International journal of molecular sciences · 2024Review
- Polycaprolactone microparticles for the subcutaneous administration of cannabidiol: in vitro and in vivo release.Drug delivery and translational research · 2024Article
- Strategies to Improve Cannabidiol Bioavailability and Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Enhanced oral bioavailability of cannabidiol by flexible zein nanoparticles:Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabidiol (CBD) is highly lipophilic, and its oral bioavailability is known to be very low in humans. In this study, we developed a novel nanoemulsion preparation of CBD (CBD-NE) to improve the poor solubility and absorption of CBD. The pharmacokinetic profiles of CBD in rats were evaluated after oral administrations of CBD oil and CBD-NE, and the effect of bile secretion on CBD absorption was also evaluated.
methodsThe CBD-NE formulation developed in this study consisted of vitamin E acetate, ethanol, Tween-20, and distilled water (1.7/3.8/70/24.5, w/w%). A CBD oil formulation (CBD oil, control) 100 mg/kg or CBD-NE 50 mg/kg was orally administered to rats, and the blood samples were collected over time. Moreover, the CBD oil or CBD-NE was orally administered to bile-fistulated rats, and the pharmacokinetic profiles of CBD were also evaluated. CBD concentrations in plasma were measured using LC-MS/MS.
resultsThe particle size of CBD-NE was 35.3 ± 11.8 nm. Mean T
conclusionsThe novel NE formulation developed in this study successfully improved the absorption of CBD regardless of bile secretion. The newly developed oral CBD-NE preparation could be useful to achieve a more stable and quicker onset of action by CBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.